

Virtual reality group therapy for depression

Submission date 25/08/2020	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 03/09/2020	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 17/03/2021	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims:

Non-attendance to group therapy is a significant issue for patients with depression. To improve access to group therapy, the NHS has recommended the use of digitally enabled therapies such as mobile application-based self-help. These therapies aim to reduce the cost of services, time and travel associated with treatment, and the perceived stigma of having to go to a treatment centre.

Virtual reality is a technology that allows users to experience computer-generated environments within a controlled setting. Users can access these computer-generated environments by inserting their smartphone into a head-mounted display (goggles), e.g. Samsung Gear VR. This technology is a feasible, acceptable, and cost-effective tool in the treatment of several different mental health disorders.

In this study, virtual reality will be used to deliver and receive group therapy remotely. The patients and the therapist will access the group at home using a goggle with smartphone insertion and an online application called vTime (vTime, Limited, 2018). During group therapy, the therapists and the patients would be anonymous and represented by an avatar (an abstract character). The Virtual Reality Group Therapy sessions will consist of 3 patients and one therapist. The treatment will consist of 8 sessions delivered once a week for 45 minutes.

This study aims to assess the functionality, feasibility and acceptability of the Virtual Reality Group Therapy intervention.

Who can participate?

Adult patients that have a diagnosis of mild to moderate depression

What does the study involve?

The Virtual Reality Group Therapy will consist of 8 sessions delivered once a week for 45 minutes. A single sample of 6-8 participants will be asked to complete the same questionnaires and measures at the start and end of the trial. Then, to assess the feasibility and acceptability of the Virtual Reality Group Therapy sessions, the participants will be invited to take part in a semi-structured interview.

What are the possible benefits and risks of participating?

Possible benefits include:

1. Improved accessibility/convenience as participants would receive treatment remotely from home. The remote nature of the treatment might especially benefit patients who struggle to leave the house due to physical disabilities (e.g. bedbound or wheelchair using patients, who lack the motivation to leave the house, who work during service hours, and who live in remote locations).
2. Patient engagement during treatment as during Virtual Reality Group Therapy, the therapists and the patients would be anonymous and represented by an avatar. This could potentially improve therapeutic engagement. Avatars increase the anonymity of patients, reduce the perceived stigma of attending group treatment, and limit the non-verbal cues received from other group members. All of this contributes to patients having more open and honest conversations in the group, leading to better therapeutic engagement.
3. Potential cost-savings of virtual treatment as Virtual Reality Group Therapy would be delivered remotely, so therapists would no longer need large buildings with multiple rooms to provide group therapy, and patients would no longer have to pay for travel. As a result of the remote nature of the treatment, patients may no longer be limited to services offered in their Borough, but could also access specialised services delivered in different Boroughs. This could potentially lead to distributing specialist resources across the country.

Possible risks include:

1. Cyber-sickness as during treatment, patients will be asked to join a virtual environment by wearing a head-mounted-display (goggle) with a mobile phone insertion. The HMD is a Conformite Europeene (CE) marked consumer product that is widely available in stores; therefore, it conforms with health and safety standards. If used for very long durations, virtual reality could induce cybersickness, which is a form of motion sickness with symptoms such as nausea and disorientation. To reduce risks of cybersickness, the virtual reality treatment sessions have been limited to 45 minutes. Furthermore, the virtual environments selected for therapy are serene locations which patients will experience seated. These factors will further reduce any possibility of cybersickness.

This treatment will be delivered remotely; patients will access this treatment online from home. Similar to all treatments offered online, there is an issue of managing any patient risk remotely (e.g. self-harm or suicide). The study eligibility criteria have been designed to limit any risks that may arise during treatment. The intervention will be delivered by a senior group therapist who has experience providing online treatment. The therapist is fully trained in risk management and NHS Trust safety policies. Risks such as suicide will be checked before each session, and if the therapists identify a need, a follow-up call will be given to the patient to manage the risk.

Where is the study run from?

The study will be run from the Unit for Social and Community Psychiatry (UK). The unit is jointly operated by Queen Mary University of London and East London NHS Foundation Trust.

When is the study starting and how long is it expected to run for?

From October 2020 to March 2021

Who is funding the study?

This study is funded by East London NHS Foundation Trust (UK) as part of the researchers PhD

Who is the main contact?

Mrs Merve Dilgul

m.dilgul@qmul.ac.uk

Contact information

Type(s)

Scientific

Contact name

Mrs Merve Dilgul

ORCID ID

<http://orcid.org/0000-0002-1207-3253>

Contact details

Unit for Social and Community Psychiatry
Newham Centre for Mental Health
Cherry Tree Way
London
United Kingdom
E13 8SP
+44 (0)2075404380 ext: 2338
m.dilgul@qmul.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil Known

IRAS number

287460

ClinicalTrials.gov number

Nil Known

Secondary identifying numbers

IRAS 287460

Study information

Scientific Title

Virtual Reality Group Therapy for Depression: A proof of concept feasibility study

Acronym

VRGT

Study objectives

1. To assess the functionality of the Virtual Reality Group Therapy intervention
2. To assess the feasibility and acceptability of the Virtual Reality Group Therapy intervention

Ethics approval required

Old ethics approval format

Ethics approval(s)

Pending, ethical approval will be sought from a Health Research Authority Research Ethics Committee by October 2020

Study design

Single-centre interventional proof-of-concept trial repeated measures design

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Internet/virtual

Study type(s)

Treatment

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Mild to moderate depression

Interventions

Virtual reality will be used to deliver and receive group therapy remotely. The patients and the therapist will access the group at home using a head-mounted display with smartphone insertion and an online application called vTime (vTime, Limited, 2018). During group therapy, the therapists and the patients would be anonymous and represented by an avatar (an abstract character). The VRGT sessions will consist of 3 patients and one therapist. The treatment will consist of 8 sessions delivered once a week for 45 minutes.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Oculus Gear VR

Primary outcome measure

1. Functionality and feasibility of the intervention calculated using the following:
 - 1.1. Recruitment rates collected using an excel recruitment spreadsheet at the end of recruitment.
 - 1.2. Treatment attendance rates collected using treatment adherence log between baseline and 8 weeks
 - 1.3. Reasons for drop-out collected using treatment adherence log between baseline and 8

weeks

1.4. Interest in VR treatment collected using interest in VR questions at baseline/enrolment and 8 weeks

1.5. Therapeutic relationship using the Working Alliance Inventory at 8 weeks or point of drop-out.

1.6. Acceptability using a client satisfaction questionnaire at 8 weeks or at point of drop out.

2. Self-reported measure of depression measured using the Patient Health Questionnaire-9 (PHQ-9) will be collected at baseline, before each treatment session at 1, 2, 3, 4, 5, 6, 7, and 8 weeks, and post-intervention after 8 weeks.

Secondary outcome measures

1. User experiences of VRGT explored qualitatively through interviews at 8 weeks

Overall study start date

03/03/2020

Completion date

29/03/2021

Eligibility

Key inclusion criteria

1. Referral from primary care for the treatment of mild to moderate depression (stepped 2).
2. No history of ongoing suicidal attempts or current tendency towards self-harm
3. Able to understand written and verbal English
4. Eligible for group therapy
5. Aged ≥ 18 years
6. Access to a smartphone
7. Access to Wi-Fi at home
8. Has an email account
9. Capacity to give consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

6-8

Key exclusion criteria

1. Unwilling or unable to give consent
2. Having a diagnosis of depression with psychotic symptoms (ICD-10: F32.3 and F33.3)

3. Associated diagnosis of an organic or neurodevelopmental disorder
4. Participation in another trial

Date of first enrolment

10/10/2020

Date of final enrolment

10/11/2020

Locations

Countries of recruitment

England

United Kingdom

Study participating centre**Newham Talking Therapies**

Vicarage Lane Health Centre

10 Vicarage Lane

Stratford

London

United Kingdom

E15 4ES

Sponsor information

Organisation

Queen Mary University of London

Sponsor details

Joint Research Management Office

5 Walden Street

London

England

United Kingdom

E1 2EF

+44 (0)20 7882 7275/6574

research.governance@qmul.ac.uk

Sponsor type

University/education

Website

<http://www.qmul.ac.uk/>

ROR

<https://ror.org/026zzn846>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

East London NHS Foundation Trust

Results and Publications

Publication and dissemination plan

Once the study receives ethical approval the protocol will be published in a peer-review journal. The researcher will publish the study in a peer review journal in collaboration with the study team. Findings will also be presented at relevant conferences and through the Unit for Social and Community Psychiatry's Twitter account. Finally, the study will form a chapter in the CI's PhD thesis.

Intention to publish date

05/05/2022

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date